Starting from these notions and our data indicating a negative correlation between uL3 expression and SLC7A11 expression (Figure 3 and Figure 4a–c), we investigated the antiproliferative activity of a combined treatment of erastin plus a plasmid encoding uL3 in uL3-silenced CRC cells. The gene discussed is SLC7A11; the disease is colorectal carcinoma.